# DeepSeek V4 Pro (0813) — deep_reasoning/ethical_dilemma_structured

- model_id: `deepseek/deepseek-v4-pro-0813`
- success: True  | final: 4.83 | quality: 5.0
- latency_total: 136.301s | tokens_per_second: 60.1
- input_tokens: 274 | output_tokens: 8192

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa

We need answer in Spanish. Need structure analysis. User asks: AI startup has model cancer detection 95% accuracy. However:
- 5% false positives cause severe anxiety and unnecessary procedures
- Model works worse on dark skin (90% accuracy vs 97% light skin)
- Launch now saves lives but with known bias
- Wait 6 months to correct bias means people will die meanwhile

Board asks recommendation. Structure:
1 Identify stakeholders affected
2 Analyze trade-offs quantitatively
3 Provide 3 options with pros/cons each
4 Final recommendation with justification
No "correct" answer; best argued.

Need craft nuanced. We need maybe assume some numbers? Need quantify trade-offs. We have precision? They say 95% accuracy but then false positives 5%. Need clarify accuracy vs false positive rate. They say "5% de falsos positivos" maybe means false positive rate 5%? "95% precision" might mean sensitivity? Ambiguous. Need maybe state assumptions. We can use hypothetical prevalence to quantify. Need analyze quantitatively. Need maybe define: if cancer prevalence in screened population e.g., 1% or 5%. We need compute outcomes for 100,000 screened. Accuracy 95%, false positive 5%, false negative? They mention "95% de precisión" but "5% de falsos positivos" maybe overall accuracy? Need carefully. We can use sensitivity/specificity? Let's parse.

"modelo puede detectar cancer con 95% de precision. Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)"

Maybe "95% precision" means accuracy overall. "5% false positives" could be false positive rate. But if accuracy 95%, false positives 5%? If prevalence low, accuracy may be high due true negatives. Need maybe model confusion matrix. For cancer detection, precision (PPV) vs recall. In Spanish "precisión" often accuracy. They mention false positives 5%. Let's assume "95% accuracy" and "5% false positive rate" maybe inconsistent? If false positive rate = 5%, false negative = ? Accuracy = (TP+TN)/N. Need prevalence.

Need maybe construct a quantitative analysis: Suppose prevalence 1%. For 100,000 people:
- With 95% sensitivity and 95% specificity? Actually "95% accuracy" not enough. "5% false positives" means specificity 95%. If sensitivity 95%? Then:
Prevalence 1%: diseased 1,000; healthy 99,000.
True positives = 950; false negatives = 50.
True negatives = 94,050; false positives = 4,950.
Total correct = 95,000 (95% accuracy). False positives 4,950, false negatives 50.
Thus for every true positive, ~5.2 false positives. That causes anxiety/procedures.
Now subgroup performance: dark skin accuracy 90% vs light 97%. Need assume same FP/FN? Could assume sensitivity lower? They say works worse. Need maybe analyze if accuracy 90% -> if specificity same 95%, sensitivity maybe? For dark skin prevalence maybe? Need compute by subgroup. Need maybe use sensitivity/specificity? If overall accuracy 95 and FP 5%; for dark skin accuracy 90 could be due lower sensitivity or specificity. Need perhaps calculate disparity. We can assume for dark skin: sensitivity 80%? specificity 90? Let's derive.

Need maybe "trade-offs quantitative": Use estimates:
- Benefits: true positives caught early, survival gain. Need maybe assume early detection reduces mortality by e.g., 20% absolute? Or lives saved per 1000 cancers. Need not exact? But user asks quantitatively. We can create hypothetical but justified. Need perhaps state assumptions explicitly.

Could use QALYs maybe. Need maybe calculate lives saved now vs delay.

Let's define a base scenario for 100,000 screened, prevalence 1%, sensitivity 95%, specificity 95%. Launch now overall:
- TP 950, FN 50, FP 4,950, TN 94,050.
- For dark skin subgroup (assuming 30% of population? or 30,000) accuracy 90%, maybe sensitivity 80%, specificity ~? Let's compute if prevalence 1%, and dark skin accuracy 90. If specificity 95? Accuracy = (TP+TN)/N = (sensitivity*prev + specificity*(1-prev)). Set accuracy .90 = sensitivity*0.01 + 0.95*0.99 = 0.01*sens + 0.9405 => sensitivity = negative? 0.90 - 0.9405 = -0.0405/0.01 = -4.05 impossible. So if specificity 95% and prevalence 1%, maximum accuracy with sensitivity 1 is .01 + .9405=95.05%, so 90% accuracy implies much lower specificity or prevalence higher. If prevalence 10%, accuracy .90 = sens*0.1 + spec*0.9. If spec 95%, sens would need .45. Could be. Hmm.

Maybe they mean "precision" as PPV? In Spanish "precision" maybe accuracy but could be positive predictive value. "5% de falsos positivos" maybe among positives? Actually "falsos positivos causa ansiedad" maybe false positive rate among healthy. Need maybe not overcomplicate. Could state ambiguity and use assumptions.

Maybe better: Use "precision" as positive predictive value? If model says cancer, 95% are true cancer, 5% false positives. That's PPV = 95%. But "5% de falsos positivos" exactly PPV false discovery rate. Then for dark skin PPV? "90% precision vs 97% en piel clara" suggests positive predictive value? Actually "precision" in ML is TP/(TP+FP). That's PPV. They say 95% precision; false positives 5% among positive predictions. Then "works worse on dark skin (90% precision vs 97%)" might mean PPV different. That makes sense in ML/startup context. Need maybe use ML precision. But false positives cause anxiety. Need also sensitivity/recall? Not given. We only know precision. To quantify lives saved, need sensitivity/recall (detect cancer). Not enough. We can assume sensitivity maybe? Hmm.

The prompt says "puede detectar cancer con 95% de precision. Sin embargo: El 5% de falsos positivos..." That likely conflates accuracy and false positives. We need maybe handle ambiguity: "Primero, distingo precisión técnica (PPV) de exactitud global. Para el análisis cuantitativo asumiré..." This will be strong.

Need maybe use decision-theory: expected lives saved vs harms. We can quantify with variables and maybe choose numbers. Need "best argued" not necessarily exact.

Let's outline:

1. Stakeholders:
- Pacientes (subgrupos: piel clara/oscura, falsos positivos, falsos negativos)
- Médicos/radiólogos/personal clínico
- Startup/board/inversores
- Reguladores (FDA/EMA/CE)
- Sistemas de salud/pagadores/aseguradoras
- Sociedad/comunidades minoritarias/defensores de equidad
- Familias/cuidadores
- Competidores? maybe.

Need maybe include direct and indirect.

2. Quantitative trade-offs:
Need define metrics:
- Prevalence p.
- Population screened N = 100,000.
- Assume sensitivity s, specificity e. Overall accuracy 95%, false positive rate 5%: specificity 95%. Need assume sensitivity 95% for symmetry? Then as above.
- For dark skin: accuracy 90% vs light 97. Need maybe model: Let population 30% dark skin, 70% light. Overall accuracy 95. If light accuracy 97, dark 90, weighted average = .7*97 + .3*90 = 67.9 + 27 = 94.9 ≈ 95. Good. So consistent. Need derive subgroup false positive/negative? We can assume specificity light 97? Hmm.

Maybe compute per subgroup using same false positive rate? If accuracy 97 for light skin with prevalence 1%, specificity must be high. If sensitivity 95%, to get accuracy 97: accuracy = 0.01*0.95 + spec*0.99 = 0.0095 + 0.99 spec = 0.97 => spec = (0.970 - 0.0095)/0.99 = 0.9702. So specificity ~97%. For dark skin accuracy 90: if sensitivity 90? Actually if specificity maybe 90% and sensitivity 90%? Accuracy with prevalence 1% = 0.01*0.90 + 0.90*0.99 = 0.009 + 0.891 = 0.900. So dark: sensitivity 90%, specificity 90%. Light: sensitivity 95%, specificity 97%. This yields overall? Weighted:
Light (70k): TP = 0.95*700=665; FP = 3% of 69,300 = 2,079; TN = 67,221; FN=35.
Dark (30k): diseased 300; TP=270; FN=30; FP=10% of 29,700 = 2,970; TN=26,730.
Total TP=935; FN=65; FP=5,049; TN=93,951; Accuracy = (935+93,951)/100k=94,886? Actually 935+93951=94886, accuracy 94.886%≈95. FP rate overall=5049/99000=5.1%. Good. This matches overall 95% accuracy and 5% FP. Dark vs light: light accuracy = (665+67221)/70000=67,886/70,000=96.98%; dark = (270+26730)/30000=27,000/30,000=90%. Great. This is a consistent set of assumptions:
- Light skin: sensitivity 95%, specificity 97%.
- Dark skin: sensitivity 90%, specificity 90%.
- Prevalence 1%.
Overall sensitivity = 935/1000=93.5%; specificity = 93,951/99,000=94.9%. Accuracy 94.9%; false positives = 5,049 (5.1% of healthy).

This is useful. Need maybe present as "supuestos para cuantificar, dado que el enunciado no da sensibilidad por subgrupo; elijo el escenario más simple consistente con 95% exactitud global, 5% FP y las exactitudes por subgrupo." Need maybe mention if actual numbers differ, recompute.

Now quantify outcomes:
- True positives detected: 935 of 1,000 cancers; false negatives: 65 missed.
- False positives: 5,049 healthy people subjected to anxiety/procedures.
- Ratio FP/TP = 5.4 false positives per true positive overall.
- Dark skin: TP 270 of 300, FN 30; FP 2,970; ratio FP/TP = 11.0. Light skin: TP 665, FP 2,079; ratio FP/TP = 3.1. So dark skin patients get far more false positives per true detected, and lower sensitivity (90% vs 95%). That's the bias.

Need maybe compute lives saved/harmed:
Assume early detection reduces cancer mortality by e.g., 20% (relative risk reduction). Then among true positives, lives saved = 935*0.20 = 187 lives saved per 100k screened. But false negatives: 65 cancers missed; if they would have been saved if detected early, potential lost lives = 65*0.20 = 13 avoidable deaths. False positives: severe anxiety and unnecessary procedures. Assume procedure complication rate e.g., biopsy complication 1-2%, severe anxiety QALY loss. Need compute:
- 5,049 FP -> if 50% undergo invasive biopsy? maybe 2,525 biopsies. If complication rate 1%, 25 complications. Or if all undergo follow-up, anxiety.
- QALYs: False positive anxiety maybe 0.05 QALY lost per FP (short-term) = 252 QALYs. Unnecessary procedures maybe 0.1 QALY lost if invasive? Need maybe.

Need maybe compare to delay 6 months:
- If we wait 6 months to correct bias, people die meanwhile. Need estimate deaths due to delay. Suppose without screening, some cancers progress. Need quantify: Incidence? If screening 100,000 people, 1,000 cancers per year? Actually prevalence 1% in screened population. If delay 6 months, maybe those 1,000 cancers would have been detected by model now; without it, some aren't detected until later. Need assume standard care detects some. Need maybe compare model launch now vs "standard care" for 6 months.

Need maybe quantify:
- Current model now: detects 935/1000. If wait 6 months, those 1,000 people don't get model. But not all die; some get standard diagnosis. Need estimate incremental benefit of model vs standard. Suppose standard care detects 80% at same stage? Hmm.

Alternative: Use "lives saved per month" from early detection. Assume each month of delayed cancer diagnosis increases mortality risk. Need maybe create simple: If model can save 187 lives per 100k screened per year, then 6 months delay = 93.5 lives lost per 100k screened if no one screened. But if wait, after 6 months launch improved model; perhaps those cancers still found but later. Need not all lost; maybe 50% lose survival benefit due progression. Need maybe use "delay reduces benefit by X%".

Could frame as "cost of delay" in lives: If launch now saves 187 lives/100k/year. Waiting 6 months means for the cohort in that period, you lose ~half that benefit, ~94 lives/100k, assuming no alternative. But maybe you can use standard care, so net loss smaller. Need maybe mention if there is an existing standard pathway, the incremental benefit of AI over standard care matters. If standard care already detects many, delay's mortality cost is lower.

Need maybe provide quantitative trade-off between equity and utility:
- Launch now overall saves more lives (187 vs maybe improved model).
- But it disproportionately harms dark skin patients: 2,970 false positives, 30 missed cancers in 30k. If improved model fixes bias to light-skin level: dark sensitivity 95%, specificity 97%:
  - Dark TP = 285 (from 270) +15 detected; FP = 3% of 29,700 = 891 (vs 2,970) -2,079 false positives avoided; FN = 15 (vs 30).
  - Lives saved dark = 285*0.2 = 57 (vs 54 now) +3; false positives avoided 2,079, huge anxiety/procedure harm reduction.
- Overall improved model: Light same: TP 665, FP 2,079; dark TP 285, FP 891; total TP 950, FP 2,970. Lives saved = 190 (vs 187). False positives reduced from 5,049 to 2,970 (41% reduction). So improved model saves slightly more lives and much fewer harms. But delay costs some lives now.

Need maybe quantify the delay cost: If we wait 6 months, we forgo current model's benefits for 6 months. Current model vs no model: If screening 100k per year, current model saves 187 lives/year; 6 months = 93.5 lives. Improved model after 6 months saves 190 lives/year, 3 more per year. The harm reduction from improved model: 2,079 fewer false positives in dark skin per 100k; maybe QALY savings. Need compare.

But waiting doesn't mean all 93.5 lives lost; if there is standard care, some cancers will be caught. Need maybe assume current model vs standard care incremental lives saved = ? We can set sensitivity of standard care e.g., 70%? Let's estimate.

Maybe assign:
- Standard care (no AI) sensitivity 80%, specificity 100? Hmm.
Let's define "current model vs standard care" maybe. Without AI, maybe doctors detect cancer with 80% sensitivity, and false positive rate 10%? Hard.

Could simplify: "Supongamos que lanzar ahora frente a esperar produce una diferencia neta de mortalidad de X vidas por 100,000 cribados en esos 6 meses." Need choose X based on assumptions. We can set incremental early detection of AI over standard care = 15 percentage points sensitivity (from 80% to 95%). Then in 1,000 cancers, 150 additional true positives per year; mortality reduction 20% => 30 lives saved per 100k per year by AI over standard. 6 months delay = 15 lives lost per 100k. That seems more realistic than 187. Need maybe use that. Hmm.

Let's re-read user: "modelo puede detectar cancer con 95% de precision." "Lanzar ahora salvaria vidas pero con sesgo conocido." "Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto." They don't provide prevalence, standard care. To quantify, we need assumptions. We can state a base-case: prevalence 1%; screening population 100k; sensitivity/specificity as above; early detection reduces mortality 20%; current standard care has sensitivity 80%. Then compute.

Let's maybe create a coherent quantitative model:
- Assume 100,000 people screened per year, disease prevalence 1% => 1,000 cancers.
- Model current (overall): sensitivity 93.5%, specificity 94.9% -> TP 935, FN 65, FP 5,049.
- Standard care: sensitivity 80%, specificity 95%? If standard care false positive rate maybe same? Then TP 800, FN 200, FP 4,950. AI adds 135 TPs and 99 FPs? Actually FP difference 5,049 - 4,950 = 99 more false positives. Hmm.
- Early detection mortality reduction: 20% relative; so AI vs standard saves 135*0.2 = 27 lives/year per 100k.
- Wait 6 months: lose half of those = 13.5 lives per 100k (assuming no AI for 6 months). But if improved model after 6 months is better, maybe loses only 6 months of benefit. That's not huge vs harm. But prompt says "gente morira mientras tanto" perhaps maybe more.

Alternatively if no standard care? Unlikely. Need maybe mention if base assumptions change, decision changes. A robust recommendation might be conditional: "Si el modelo se va a usar como triaje complementario, esperar; si es único recurso en contexto sin acceso, lanzar con mitigaciones."

Need maybe provide 3 options:
1. Lanzar ahora con mitigaciones (consentimiento informado, auditoría, seguimiento de subgrupos, umbral ajustado por grupo, no uso autónomo).
2. Esperar 6 meses para corregir sesgo y lanzar versión validada (posible HAC/equidad).
3. Lanzamiento limitado/condicional: pilot en hospitales con alta prevalencia y capacidad de seguimiento, excluir o ajustar para piel oscura? Or "lanza ahora solo para poblaciones donde el modelo funciona con precisión aceptable y auditoría" but that raises equity? Maybe "despliegue por fases con monitoreo intensivo y ajuste continuo". Need pros/contras.

Need maybe final recommendation. Which is best argued? Need choose. I lean: lanzamiento limitado/condicional now, not full commercial launch, while fixing bias in parallel. Because it balances lives saved and equity harms. But user asks final recommendation. Need maybe "Recomendación: no lanzamiento amplio; lanzamiento condicional/piloto controlado durante 6 meses, con mitigaciones y umbral específico por subgrupo si es posible, y compromiso de corregir sesgo. Si no se puede mitigar el sesgo, esperar." That seems balanced.

Need maybe analyze options quantitatively.

Let's structure detailed.

Potential final:

**Supuestos clave** (explicit):
- "95% precisión" lo trato como exactitud global, con tasa de falsos positivos 5%. Dado que no hay matriz de confusión completa, asumo: prevalencia 1%; sensibilidad global ≈93.5%, especificidad ≈94.9%; para piel clara: sens 95%, espec 97%; para piel oscura: sens 90%, espec 90%. Esto reproduce exactitudes reportadas.
- Población: 100,000 cribados; 70% piel clara, 30% piel oscura.
- Beneficio de detección temprana: reducción de mortalidad por cáncer de 20% en verdaderos positivos.
- Pérdida de utilidad por FP: 0.05 QALY por FP (ansiedad) + 0.1 QALY por biopsia innecesaria en 50% de FP. Maybe use QALY.

Need maybe not overdo, but include.

Let's compute numbers precisely:

Population: 100,000
Prevalence 1% -> 1,000 cancer, 99,000 healthy.
Subgroup counts: Light 70,000, cancer 700; Dark 30,000, cancer 300.

Current model:
Light:
- Sensitivity 95%: TP = 665; FN = 35.
- Specificity 97%: FP = 3% of 69,300 = 2,079; TN = 67,221.
Dark:
- Sensitivity 90%: TP = 270; FN = 30.
- Specificity 90%: FP = 10% of 29,700 = 2,970; TN = 26,730.
Total:
- TP = 935; FN = 65.
- FP = 5,049; TN = 93,951.
- Accuracy = 94,886/100,000 = 94.9%.
- FP/TP overall = 5.4; dark FP/TP = 11.0; light FP/TP = 3.1.
- Lives saved (vs no detection?) = 935*0.2 = 187. But this is vs no screening. Need maybe present "vidas salvadas respecto a no cribar" not vs standard care. Maybe state.

Improved model (if bias fixed to light-skin performance for all):
Dark improved: TP = 285; FP = 891; FN = 15.
Light same: TP = 665; FP = 2,079.
Total TP = 950; FP = 2,970.
Lives saved = 190.
Difference from current: +15 TP, -30 FN? Actually current FN 65, improved FN 50? Wait light FN 35, dark improved FN 15 = 50 total. Current total FN 65. So 15 fewer false negatives. FP reduced from 5,049 to 2,970: 2,079 fewer FPs (all in dark skin). Lives saved +3 (since 15*0.2 = 3) if compared to no screening. Harms: 2,079 fewer false positives.

If delay 6 months:
Assume model saves 187 lives/year/100k vs no screening. 6 months = 93.5 lives delayed. But if standard care exists, the marginal benefit vs standard care is smaller. Let's compute with standard care sensitivity 80%, specificity 95%:
Standard care:
TP = 800; FN = 200; FP = 4,950.
Current AI marginal vs standard: TP +135, FP +99 (actually current FP 5,049 vs 4,950 = +99). Lives saved marginal = 135*0.2 = 27/year.
6-month delay loses 13.5 lives/100k marginal (if standard care continues). Improved model marginal after fix: TP +150, FP -1,980? Compared to standard: TP=950 vs 800 = +150; FP=2,970 vs 4,950 = -1,980. Lives saved marginal = 30/year. So improvement over current is +3 lives/year and 2,079 fewer FP.

But if standard care false positive rate differs? Hmm.

Need maybe present this as "dos escenarios":
- Optimista/cribado único: current model saves 187 lives/year; delay loses 94 lives per 100k in 6 months.
- Base realista (con estándar de cuidado): current model adds 27 lives/year; delay loses 14 lives per 100k in 6 months.
This is important.

Need maybe quantify QALY harm of false positives:
- 5,049 FP. Suppose 50% undergo invasive procedure (2,525), 1% complication rate -> 25 complications. Anxiety severe in all FP: 0.05 QALY each = 252 QALY. Procedures: 0.1 QALY each for 2,525 = 253 QALY. Total ~505 QALY lost per 100k.
- Wait improved model would reduce FP to 2,970; QALY loss ~297, saving ~208 QALY.
But if current model's false positives are concentrated in dark skin: 2,970 FP in dark -> QALY loss ~297 in 30k; improved would 89 QALY? Actually 891 FP -> 89 QALY, saving ~208 QALY. This is equity.

Need maybe compare lives saved vs QALY harm. 1 life saved ~ maybe 10 QALYs? If current model saves 187 lives vs no screening, QALY benefit = 187*10 = 1,870 QALY; harm 505 QALY; net +1,365 QALY. But dark subgroup: lives saved 54*10=540 QALY; FP harm 2,970*0.05 + maybe procedures 1,485*0.1 = 148.5+148.5=297 QALY; net +243 QALY. Light: lives saved 133*10=1,330; FP harm 2,079*0.05 + 1,039.5*0.1=103.95+103.95=207.9; net +1,122 QALY. So both subgroups benefit in aggregate, but dark has much lower benefit/harm ratio (1.8 vs 6.4) and 3x FP per TP. Hmm.

Need maybe not overcomplicate with QALY but can include as "análisis de utilidad simple".

Need maybe "trade-offs quantitative" includes:
- Overall clinical utility positive in base case.
- Equity gap: dark FP/TP ratio 11 vs light 3.1; dark sensitivity 90% vs light 95%; dark specificity 90% vs light 97%.
- Delay cost: 6 months lost benefit = 14–94 lives/100k depending on standard care assumption.
- Fixed model benefit: avoids ~2,079 FP/100k in dark skin; detects 15 more cancers/100k; but delay.

Need maybe final recommendation conditional:
"Mi recomendación: No lanzar comercialmente a gran escala sin corregir el sesgo. Implementar un despliegue controlado y auditado (piloto) de 6 meses, con mitigaciones: (a) umbral de decisión diferenciado por subgrupo si técnicamente posible; (b) consentimiento informado explícito para poblaciones de piel oscura; (c) canal de seguimiento rápido para falsos positivos; (d) auditoría semanal de métricas por subgrupo; (e) continuar entrenando con datos diversos. Si las mitigaciones no pueden reducir el sesgo a niveles aceptables, esperar."

Need maybe justify with numbers: The marginal benefit of launching now vs waiting 6 months is likely ~14 lives/100k (or 94 if no standard care) while the harm reduction from fixing bias is 2,079 false positives avoided in dark skin and 15 more cancers detected. A full launch now would institutionalize a known racial/ethnic disparity and could damage trust/regulatory approval. But a total wait may be unacceptable if no alternative. Therefore conditional launch.

Need maybe also mention "FDA/reguladores" might not allow known biased model; launching now could lead to liability, recalls, reputational damage. Need maybe include in options.

Need maybe produce three options:
Option A: Lanzar ahora amplio.
Pros: Inmediatez, saves lives now (e.g., 187 or 27 marginal per year per 100k), revenue, data collection.
Cons: Known bias harms dark skin; 5,049 FP (2,970 in dark); trust/legal/regulatory risk; may be forced to retract; ethical equity violation; dark FP/TP 11 vs light 3.1.

Option B: Esperar 6 meses y lanzar modelo corregido.
Pros: Equity improved, false positives reduced by ~2,079/100k, sensitivity in dark skin increases ~15 cases detected, regulatory/trust better, avoids discriminatory harm.
Cons: Delay loses 14–94 lives/100k (depending standard care); competitive/market delay; risk that "perfect" becomes enemy of "good"; model still may not fix all bias.

Option C: Lanzamiento limitado/condicional con mitigaciones y auditoría.
Pros: Captures most immediate benefit (e.g., if limited to 50% of population, saves ~7–47 lives during 6 months); reduces equity harm via adjusted thresholds, informed consent, follow-up; builds real-world evidence for fix; regulatory trust.
Cons: Operational complexity; may still cause harm in dark skin if thresholds not adjusted; may be perceived as experimentation; requires resources; may not be enough to satisfy advocates or regulators; if mitigation fails, need stop.

Need maybe maybe option C as "lanza ahora para piel clara, no para piel oscura" but that is discriminatory? Actually maybe "no lanzar en poblaciones donde no es seguro" could be an option but ethically questionable. Better not.

Need maybe final recommendation: Option C, with a hard stop if equity metrics not met in 6 months. Justify: It treats the bias as safety issue, not just statistical; it uses the 6 months to fix while not completely withholding benefit; it avoids known discriminatory harm of full launch; and quantitatively the net harm of false positives in dark skin is large relative to marginal lives saved by immediate full launch. Need maybe state "No lanzo amplio porque la relación FP/TP para piel oscura (11:1) es clínicamente inaceptable; no espero pasivamente porque la pérdida de vidas en 6 meses puede ser significativa."

Need ensure answer in Spanish, clear structure. Need maybe include disclaimers: "No soy médico; esto es análisis de decisión." Not necessary but can.

Need maybe use "precisión" as "exactitud" but mention "asumo que '95% precisión' es exactitud global; si en realidad es VPP, los números cambian." Good.

Let's craft answer elegantly.

Need maybe maybe include calculations in a table.

Let's produce final with sections.

Potential final:

```
Supuestos para cuantificar (explícitos):
- Población cribada: 100,000; prevalencia cáncer 1%.
- 70% piel clara, 30% oscura.
- Modelo actual consistente: clara sens 95%, espec 97%; oscura sens 90%, espec 90%. Esto da exactitud global 94.9%, FP global 5.1%.
- Reducción de mortalidad por detección temprana: 20% (RRR).
- Estándar de cuidado alternativo: sens 80%, espec 95%.
```

Need maybe "La elección de 70/30 y 20% es ilustrativa; si cambian, el análisis debe recalcularse."

Then stakeholders.

Then trade-offs table.

Let's compute exact values in table:
Current model:
- Light: TP 665, FN 35, FP 2079, TN 67221, acc 96.98%
- Dark: TP 270, FN 30, FP 2970, TN 26730, acc 90.0%
- Total: TP 935, FN 65, FP 5049, TN 93951, acc 94.9%
- FP/TP: light 3.1; dark 11.0; total 5.4.

Improved model (bias corregido a nivel clara):
- Dark: TP 285, FN 15, FP 891, TN 28809? Wait TN = 29,700 - 891 = 28,809. Acc = (285+28,809)/30,000 = 29,094/30,000 = 96.98%.
- Total: TP 950, FN 50, FP 2,970, TN 96,030? Let's compute total healthy 99,000; FP 2,079+891=2,970; TN 99,000-2,970=96,030. Total correct = 950+96,030=96,980; acc 96.98%.
Difference: TP +15; FP -2,079 in dark; FN -15.

Lives saved vs no screening:
Current 187; improved 190; difference +3.
But vs standard care:
Current marginal TP over standard 135 -> 27 lives/year; improved marginal TP 150 -> 30 lives/year. Difference +3 lives/year.
Delay 6 months: lose 13.5 lives/100k (if standard care) or 93.5 (if no standard).

QALY harm maybe:
Current FP 5,049. Suppose each FP: 0.05 QALY anxiety; 50% biopsy: 2,525*0.1 = 252.5; total 252.45+252.5=504.95 ≈505 QALY lost.
Improved FP 2,970: 148.5+148.5=297 QALY lost.
Reduction: 208 QALY per 100k.
Dark current FP 2,970 -> 297 QALY; improved dark FP 891 -> 89.1 QALY; reduction 208 QALY in dark (same). This is significant.

Need maybe if standard care FP 4,950, then current AI adds 99 FP, improved reduces 1,980 FP compared to standard. Hmm maybe mention.

Need maybe "El beneficio neto clínico actual es positivo en promedio, pero la distribución es desigual." Good.

Options table:

Option A: Lanzamiento amplio inmediato.
Pros:
- Beneficio inmediato: 187 vidas/100k/año vs no cribado (27 vs estándar).
- Datos reales, ingresos, feedback.
- Evita retraso.
Cons:
- 5,049 FP/100k; 2,970 en piel oscura.
- FP/TP en piel oscura 11:1; riesgo de daño desproporcionado.
- Riesgo regulatorio, legal, reputacional; pérdida de confianza en comunidades.
- El sesgo puede congelarse si el producto se usa ampliamente.

Option B: Esperar 6 meses para corregir sesgo.
Pros:
- Elimina/reduce inequidad: 2,079 FP menos en piel oscura; +15 cánceres detectados.
- Mejor validación, confianza, aceptación regulatoria.
Cons:
- Retraso de 6 meses: 14–94 vidas/100k no salvadas.
- Si el modelo actual es el único acceso, el costo ético de no lanzar puede ser alto.
- Competencia/mercado.
- Riesgo de que la corrección no sea perfecta.

Option C: Despliegue condicional/piloto controlado con mitigaciones (recomendado).
Mitigaciones: umbral específico por subgrupo, consentimiento informado, seguimiento de FP, auditoría por subgrupo, entrenamiento continuo, limitar a hospitales con capacidad de gestionar falsos positivos.
Pros:
- Captura parte del beneficio (si piloto cubre 50%: 7–47 vidas/100k durante 6 meses? Need compute: if 50% of population, current vs standard saves 13.5 lives/year? Wait current marginal 27/year per 100k. For 6 months half population = 27/2*0.5? Actually 27 lives/year per 100k. For 50k over 6 months: 27*0.5*0.5 = 6.75 lives. If no standard: 187*0.5*0.5=46.75. So 7–47 lives. Good.)
- Reduce daño: excluir o ajustar para piel oscura si no se puede asegurar equidad; seguimiento rápido.
- Genera evidencia para corregir sesgo.
Cons:
- Complejidad operativa.
- Si no se ajusta umbral, aún puede dañar a piel oscura.
- Requiere inversión; puede retrasar comercialización completa.
- Reguladores pueden exigir más.

Need maybe final recommendation: Option C with conditions:
- Lanzamiento piloto solo si se cumplen métricas mínimas por subgrupo: e.g., FP/TP ratio ≤5 for dark skin? Actually current dark 11. Need adjust threshold to reduce FP maybe at cost sensitivity. Could set: if threshold adjustment can achieve dark specificity 95%